Samsara BioCapital, LLC

PALO ALTO, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$1.05B2026 Q3
Positions27
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.87.9%

Samsara BioCapital, LLC reported 27 positions worth $1.05B as of September 30, 2026 (13F filed November 16, 2026). Largest holding: SRRK (31.7%). Biggest move: new buy PMVP ($12.1M).

10 / 27 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 SRRKScholar Rock$333.3M31.69%6,897,652——-7.8%
▸ 2 MLYSMineralys Therapeutics$147.5M14.03%5,871,018——-39.0%
▸ 3 SEPNSepterna$120.0M11.41%3,066,453——+6.5%
▸ 4 ALMRAlamar Biosciences$84.5M8.04%2,480,310——-10.3%
▸ 5 SGPSpyGlass Pharma$54.9M5.22%2,109,953———
▸ 6 ALMSAlumis$53.5M5.08%7,235,809——-30.4%
▸ 7 NGNENeurogene$51.9M4.94%1,867,127——-14.0%
▸ 8 KLRSKalaris Therapeutics$37.2M3.54%12,881,175———
▸ 9 IVAInventiva S.A.$23.3M2.22%6,314,805———
▸ 10 PBLSParabilis Medicines$18.0M1.71%556,044——-13.8%

Pro Feature

The remaining 17 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Samsara BioCapital, LLC hold as of Q3 2026?

Samsara BioCapital, LLC reported 27 positions worth $1.05B in its Q3 2026 13F filing. Largest positions: SRRK (31.7%), MLYS (14.0%), SEPN (11.4%), ALMR (8.0%) and SGP (5.2%).

What did Samsara BioCapital, LLC buy in Q3 2026?

New positions: PMVP, OBX, TCGX ACQUISITION CORP and GOSSAMER BIO INC . Added to: ALMS, NGNE and VTVT.

What did Samsara BioCapital, LLC sell in Q3 2026?

Reduced: SEPN, AQST, UPB, XFOR and AGMB (6 in all). Sold out entirely: GOSS.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.